Fundraising Fox

Converge Bio

Claymont, US · Founded 2024 · Delaware corporation · 2 known investors

converge-bio.com ↗

Converge Bio develops generative AI models trained on DNA, RNA, and protein sequences to support drug discovery and development for biotech and pharmaceutical companies. The company provides AI solutions for target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.

AI & Machine LearningBiotechDeep Techin /converge-bio

Founders & leadership

DGDov Gertz
Dov GertzinExecutive Officer, Director
OKOded Kalev
Oded KalevinExecutive Officer, Director
IWIddo Weiner
Iddo WeinerinExecutive Officer
STShahar Tzafrir
Shahar TzafririnDirector
AHAndrew Hedin
Andrew HedininDirector

Investors · 2

Bessemer Venture PartnersRedwood City · $5M – $100M
TLV PartnersTel Aviv · $3M – $70M

Reported raises · per SEC filings

Form D private placements
▶$25MraisedApr 2026 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shahar TzafrirDirector
  • Dov GertzExecutive Officer, Director
  • Oded KalevExecutive Officer, Director
  • Andrew HedinDirector
  • Iddo WeinerExecutive Officer
Offering amount
$25M
Amount sold
$25M
First sale
Sep 2025
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news